Cytotoxic NK/CD8 T cells interact with MHC-I ligands on tumor cells through either activating or inhibiting receptors. One of the inhibitory receptors is CD94/NKG2A. The NK/CD8 T cell cytotoxic capability is lost when tumor-associated human leukocyte antigen， HLA-E， binds the CD94/NKG2A receptor， resulting in tumor progression and reduced survival. Failure of cancer patients to respond to natural killer (NK) cell therapies could be due to HLA-E overexpression in tumor tissues. Preventing the inhibitory receptor-ligand interaction by either receptor- or ligand-specific monoclonal antibodies (mAbs) is an innovative passive immunotherapeutic strategy for cancer. Since receptors and ligands can be monomeric o... More
Cytotoxic NK/CD8 T cells interact with MHC-I ligands on tumor cells through either activating or inhibiting receptors. One of the inhibitory receptors is CD94/NKG2A. The NK/CD8 T cell cytotoxic capability is lost when tumor-associated human leukocyte antigen， HLA-E， binds the CD94/NKG2A receptor， resulting in tumor progression and reduced survival. Failure of cancer patients to respond to natural killer (NK) cell therapies could be due to HLA-E overexpression in tumor tissues. Preventing the inhibitory receptor-ligand interaction by either receptor- or ligand-specific monoclonal antibodies (mAbs) is an innovative passive immunotherapeutic strategy for cancer. Since receptors and ligands can be monomeric or homo- or heterodimeric proteins， the efficacy of mAbs may rely on their ability to distinguish monospecific (private) functional epitopes from nonfunctional common (public) epitopes. We developed monospecific anti-HLA-E mAbs (e.g.， TFL-033) that recognize only HLA-E-specific epitopes， but not epitopes shared with other HLA class-I loci as occurs with currently available polyreactive anti-HLA-E mAbs. Interestingly the amino acid sequences in the α1 and α2 helices of HLA-E， critical for the recognition of the mAb TFL-033， are strikingly the same sequences recognized by the CD94/NKG2A inhibitory receptors on NK/CD8 cells. Such monospecific mAbs can block the CD94/NKG2A interaction with HLA-E to restore NK cell and CD8 anticancer cell cytotoxicity. Furthermore， the HLA-E monospecific mAbs significantly promoted the proliferation of the CD4/CD8 T cells. These monospecific mAbs are also invaluable for the specific demonstration of HLA-E on tumor biopsies， potentially indicating those tumors most likely to respond to such therapy. Thus， they can be used to enhance passive immunotherapy once phased preclinical studies and clinical trials are completed. On principle， we postulate that NK cell passive immunotherapy should capitalize on both of these features of monospecific HLA-E mAbs， that is， the specific determination HLA-E expression on a particular tumor and the enhancement of NK cell/CD8 cytotoxicity if HLA-E positive.
